Login to Your Account



Payload crossroads: Bind unveils phase II, enlisting bank to plot the way forward

By Randy Osborne
Staff Writer

Wednesday, April 6, 2016

Bind Therapeutics Inc.'s lead docetaxel compound from the Accurin platform is "certainly not the future story" of the company, CEO Andrew Hirsch told BioWorld Today, "and I'm not convinced was the best application of the platform, given some of the limitations of the payload."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription